| A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer (NCT02146313) | Genentech, Inc. | 2014-06-22 |
| Blood Collection From People With Ovarian Cancer (NCT02063464) | National Cancer Institute (NCI) | 2014-03-10 |
| A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (NCT01905592) | Tesaro, Inc. | 2014-02-25 |
| DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics (NCT02288676) | McGill University | 2014-01-01 |
| Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma (NCT02107950) | SOTIO a.s. | 2013-11-01 |
| Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma (NCT02107937) | SOTIO a.s. | 2013-11-01 |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT01846611) | Janssen Research & Development, LLC | 2013-10-16 |
| Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis (NCT03193671) | Göteborg University | 2013-09-01 |
| A Study Of PF-06263507 In Patients With Advanced Solid Tumors (NCT01891669) | Pfizer | 2013-08-08 |
| Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer (NCT01881451) | British Columbia Cancer Agency | 2013-08-01 |
| A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer (NCT01847274) | Tesaro, Inc. | 2013-06-21 |
| 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients (NCT01832116) | University Medical Center Groningen | 2013-03-01 |
| 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant (NCT01766622) | National Institutes of Health Clinical Center (CC) | 2012-11-30 |
| A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer (NCT01654458) | Women's College Hospital | 2012-07-01 |
| A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer (NCT01616303) | Quest PharmaTech Inc. | 2012-06-15 |
| STELLA Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer (NCT01810874) | Hospital Universitari Vall d'Hebron Research Institute | 2012-06-01 |
| Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer (NCT01628380) | A.O. Ospedale Papa Giovanni XXIII | 2012-06-01 |
| DOvEE - Diagnosing Ovarian & Endometrial Cancer Early (NCT02296307) | McGill University | 2012-01-01 |
| A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors (NCT01478685) | Celgene | 2011-11-29 |
| Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer (NCT01462890) | AGO Study Group | 2011-11-01 |
| Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma (NCT01460979) | AGO Study Group | 2011-10-01 |
| Amatuximab for High Mesothelin Cancers (NCT01413451) | National Cancer Institute (NCI) | 2011-07-12 |
| Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy (NCT01384253) | Orano Med LLC | 2011-07-01 |
| Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC) (NCT01329549) | Boehringer Ingelheim | 2011-04-01 |
| BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer (NCT01314105) | Boehringer Ingelheim | 2011-03-15 |
| Early Detection of Cancers in Low Resource Countries (NCT01178736) | Woman's Cancer Foundation | 2011-03-01 |
| Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer (NCT01279291) | Kyowa Kirin Co., Ltd. | 2011-01-01 |
| A Prospective Trial of COXEN Chemotherapy Prediction (NCT01228942) | University of Virginia | 2010-10-01 |
| BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer (NCT01121406) | Boehringer Ingelheim | 2010-04-01 |
| A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer (NCT01095848) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2010-03-01 |
| Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer (NCT01313078) | National Cancer Institute (NCI) | 2010-01-01 |
| LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer (NCT01015118) | Boehringer Ingelheim | 2009-11-17 |
| A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer (NCT01016054) | Astellas Pharma Inc | 2009-10-01 |
| Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma (NCT00976183) | Gynecologic Oncology Associates | 2009-10-01 |
| A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer (NCT00913835) | Eli Lilly and Company | 2009-06-01 |
| A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors (NCT00841191) | Centocor, Inc. | 2009-03-01 |
| Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer (NCT00719212) | Translational Research in Oncology | 2009-01-01 |
| Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer (NCT00718523) | Translational Research in Oncology | 2009-01-01 |
| Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer (NCT00791778) | Bayer | 2008-11-01 |
| A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer (NCT00816764) | Astellas Pharma Inc | 2008-10-01 |
| A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers (NCT00698451) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2008-08-01 |
| Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer (NCT00628251) | AstraZeneca | 2008-07-30 |
| AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer (NCT00610714) | AstraZeneca | 2008-04-01 |
| Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients (NCT01523652) | Azienda Ospedaliera San Giovanni Battista | 2007-11-01 |
| A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020) (NCT00746694) | Merck Sharp & Dohme LLC | 2007-10-01 |
| Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer (NCT00919984) | Korea Cancer Center Hospital | 2007-05-01 |
| Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer (NCT00473954) | EGEN, Inc. | 2007-04-01 |
| Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00445549) | National Cancer Institute (NCI) | 2007-01-01 |
| Pharmacogenomics of Paclitaxel in Ovarian Cancer (NCT00415207) | University of Southern Denmark | 2006-12-01 |
| ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma (NCT00407407) | Celgene | 2006-11-01 |
| AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites (NCT00396591) | Sanofi | 2006-10-01 |
| Pharmacogenomics of Paclitaxel in Ovarian Cancer (NCT00415181) | University of Southern Denmark | 2006-09-01 |
| Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis (NCT00243685) | Pierian Biosciences | 2006-09-01 |
| ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer (NCT00325351) | Bayer | 2006-08-24 |
| Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites (NCT00327444) | Sanofi | 2006-07-01 |
| Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer (NCT00350948) | Telik | 2006-05-01 |
| Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas (NCT00443196) | Pierian Biosciences | 2006-03-01 |
| A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer (NCT00710762) | Boehringer Ingelheim | 2006-03-01 |
| Tissue Bank of Biological Specimens From Patients With Gynecologic Disease (NCT00299481) | U.S. Army Medical Research and Development Command | 2006-03-01 |
| Diagnostic Imaging of Lymph Nodes in Gynaecologic Oncology (NCT00288821) | UMC Utrecht | 2006-02-01 |
| Questionnaire Study for Gynecological Cancer Survivors (NCT00391664) | U.S. Army Medical Research and Development Command | 2006-02-01 |
| Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer (NCT00246688) | Bayer | 2005-11-01 |
| Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer (NCT00137865) | EGEN, Inc. | 2005-08-01 |
| A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP) (NCT00516373) | AstraZeneca | 2005-07-11 |
| Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy (NCT00109096) | Eli Lilly and Company | 2005-06-01 |
| Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer (NCT00130520) | University of Arizona | 2005-06-01 |
| Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian Carcinoma (NCT00531570) | NYU Langone Health | 2005-02-01 |
| Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED) (NCT00743431) | Merck Sharp & Dohme LLC | 2005-02-01 |
| Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy (NCT00216645) | Janssen Pharmaceutical K.K. | 2005-01-01 |
| Acupuncture for Women's Health Conditions (NCT00090389) | National Center for Complementary and Integrative Health (NCCIH) | 2005-01-01 |
| A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) (NCT00727961) | Merck Sharp & Dohme LLC | 2004-11-09 |
| Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers (NCT00231855) | Montefiore Medical Center | 2004-11-01 |
| An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation (NCT00132704) | Memorial Sloan Kettering Cancer Center | 2004-08-01 |
| Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients (NCT00127920) | Gynecologic Oncology Associates | 2004-08-01 |
| Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms (NCT00160472) | United States Department of Defense | 2004-03-01 |
| Establishment of a Tumor Bank for Blood Samples (NCT01763125) | Medical University of Vienna | 2003-11-01 |
| Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC) (NCT00390182) | University of Maryland, Baltimore | 2003-10-01 |
| A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) (NCT00780039) | Merck Sharp & Dohme LLC | 2003-10-01 |
| Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients (NCT01124435) | Catholic University of the Sacred Heart | 2003-10-01 |
| Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer (NCT00074867) | Pfizer | 2003-10-01 |
| Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer (NCT00772863) | Sanofi | 2003-09-01 |
| Establishment of a Tumor Bank for Tissue Samples (NCT01789229) | Medical University of Vienna | 2003-09-01 |
| Biobehavioral-Cytokine Interactions in Ovarian Cancer (NCT01113112) | Susan Lutgendorf | 2003-08-01 |
| TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer (NCT00057720) | Telik | 2003-06-01 |
| Neoadjuvant Chemotherapy With Carboplatin and Docetaxel in Patients With Advanced Ovarian Cancer-Prospective, Randomized Phase II Clinical Trial (NCT00551577) | University Hospital, Bonn | 2003-03-01 |
| TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian (NCT00539669) | Sanofi | 2003-03-01 |
| TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer (NCT00052065) | Telik | 2003-02-01 |
| TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer (NCT00051948) | Telik | 2003-01-01 |
| An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy (NCT00191646) | Eli Lilly and Company | 2002-10-01 |
| A Study of Trabectedin in Patients With Advanced Ovarian Cancer (NCT00050414) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2002-10-01 |
| Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer. (NCT00043446) | Tularik | 2002-07-01 |
| A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. (NCT00191607) | Eli Lilly and Company | 2002-07-01 |
| A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma (NCT00034138) | Unither Pharmaceuticals | 2002-03-01 |
| Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer (NCT00452985) | Sanofi | 2002-02-01 |
| EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer (NCT00035100) | Novartis Pharmaceuticals | 2001-09-01 |
| Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer (NCT00038428) | Telik | 2001-06-01 |
| Massage Therapy for Cancer-Related Fatigue (NCT00039793) | National Center for Complementary and Integrative Health (NCCIH) | 2001-03-01 |
| Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma (NCT00034372) | Unither Pharmaceuticals | 2000-09-01 |
| Institut Paoli Calmettes Ovarian Cancer Database (NCT02869568) | Institut Paoli-Calmettes | 2000-01-01 |
| Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics (NCT00341458) | National Cancer Institute (NCI) | 1999-09-01 |